Clinical Trials Directory

Trials / Completed

CompletedNCT05576597

Effect of Butyrate Supplement on Rheumatoid Arthritis

A Pilot Study to Evaluate Efficacy and Safety of Butyrate Supplement in the Treatment of Rheumatoid Arthritis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Peking University People's Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is a pilot study to evaluate the safety and efficacy of administering butyrate supplement on rheumatoid arthritis patients. Thirty participants will be included to receive butyrate supplement for 12 weeks. Changes of immune cell subtypes, markers of intestinal damage, intestinal flora and other laboratory indicators will be monitored.

Detailed description

This is a single center, uncontrolled, open-label study to assess the efficacy and safety of butyrate supplement plus standard therapy in rheumatoid arthritis(RA). The patients will be given 2 sodium butyrate capsules (containing 1200 mg of sodium butyrate) daily as supplemental therapy. The objective is to assess the effects of 12 weeks of sodium butyrate supplementation on intestinal inflammation and immune regulation in patients with RA, specifically changes in T-cell subtypes and biomarkers associated with intestinal injury. Clinical manifestations and other laboratory indices will also be monitored.

Conditions

Interventions

TypeNameDescription
DRUGSodium Butyrate2 capsules butyrate supplement once a day for 12 weeks

Timeline

Start date
2022-08-23
Primary completion
2023-10-01
Completion
2024-06-15
First posted
2022-10-12
Last updated
2024-08-22

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05576597. Inclusion in this directory is not an endorsement.